Today: 5 January 2026
Subscribe
Browse Category

Mergers and Acquisitions News 22 December 2025 - 31 December 2025

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

AI Stocks Today (Dec. 25, 2025): Nvidia’s Groq Deal, Snowflake’s M&A Talks, UiPath’s Index Boost, and Meta’s WhatsApp AI Clash

December 25, 2025 — It’s Christmas Day, U.S. markets are taking a breather, and yet the AI-stock news cycle is doing what it always does: refusing to sleep. With investors digesting a holiday-thinned week of announcements, today’s biggest AI-stock narratives
25 December 2025
····
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies Corporation (NASDAQ: DVAX) is the center of the biotech tape on Wednesday, December 24, 2025, after Sanofi announced a deal to acquire the vaccine maker in an all-cash transaction valued at roughly $2.2 billion. The headline number investors
24 December 2025
····
Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics (CWAN) Stock News on Dec. 23, 2025: $24.55 Take-Private Deal, Go‑Shop Window, Analyst Reactions, and What Investors Should Watch

Clearwater Analytics Holdings, Inc. (NYSE: CWAN) is trading like a classic merger-arbitrage stock on December 23, 2025—hovering just below the agreed buyout price after the company signed a definitive deal to go private. Shares recently changed hands around $24.06, closely
23 December 2025
····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is trading like a classic “deal stock” on December 22, 2025—hovering just below a fixed cash acquisition price after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to buy the company in an all-cash transaction. As of the
22 December 2025
····
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme (ticker ABVX on Nasdaq and Euronext Paris) is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s
22 December 2025
····
Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

Amicus Therapeutics (FOLD) Stock Week Ahead: $14.50 BioMarin Buyout Puts the Deal Spread—and New Filings—Front and Center (Dec. 22–26, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) is no longer trading like a “typical biotech story stock.” After BioMarin’s all-cash $14.50-per-share takeover agreement, FOLD has effectively become a deal-driven, merger-arbitrage name—meaning next week’s action is likely
22 December 2025
····
1 2 3 … 6
Go toTop